You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

JAK 1/2

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Alopecia Areata Trial in Sohag (Janus Kinase 1 and 2)

Recruiting
  • Alopecia Areata
  • Janus Kinase 1 and 2
  • Sohag, Egypt
    Sohag University hospitals
May 12, 2023

Severe Aplastic Anemia, Single Lineage Cytopenias, T-LGL, Hypoplastic MDS Trial run by the National Heart, Lung, and Blood

Not yet recruiting
  • Severe Aplastic Anemia
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 23, 2023

Chronic GVHD, Chronic GVHD Trial run by the NCI (Baricitinib)

Active, not recruiting
  • Chronic Graft vs Host Disease
  • Chronic Graft-Versus-Host Disease
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Nov 29, 2022

Idiopathic Inflammatory Myopathies Trial in London (Baricitinib)

Recruiting
  • Idiopathic Inflammatory Myopathies
  • London, United Kingdom
    King's College Hospital NHS Foundation Trust
May 19, 2022

Lupus Nephritis Trial in Assiut (Anti JAK1,2)

Active, not recruiting
  • Lupus Nephritis
  • Anti JAK1,2
  • Assiut, Assuit, Egypt
    Manal Hassanien
Jun 21, 2022

Diabetes, Type 1 Trial (Abrocitinib 200 MG Oral Tablet, Ritlecitinib, Placebo)

Not yet recruiting
  • Diabetes Mellitus, Type 1
  • Abrocitinib 200 MG Oral Tablet
  • +2 more
  • (no location specified)
Feb 21, 2023

Cicatricial Alopecia Trial in New York (PF-06700841, Placebo)

Recruiting
  • Cicatricial Alopecia
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Aug 16, 2022

Chronic Hand Dermatitis Trial in Rochester (Ruxolitinib)

Recruiting
  • Chronic Hand Dermatitis
  • Rochester, New York
    UR Medicine Dermatology College Town
Aug 9, 2022

Primary Myelofibrosis, Secondary Myelofibrosis Trial in Seattle (procedure, drug, other, radiation)

Active, not recruiting
  • Primary Myelofibrosis
  • Secondary Myelofibrosis
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +11 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 10, 2023

Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE), Juvenile Dermatomyositis (JDM),

No longer available
  • Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE)
  • +3 more
  • Bethesda, Maryland
  • +2 more
Apr 6, 2022

Myeloproliferative Tumor, Essential Thrombocythemia, JAK2 Mutation Trial in Ottawa (Apixaban 2.5 MG Oral Tablet [ELIQUIS],

Recruiting
  • Myeloproliferative Neoplasm
  • +5 more
  • Apixaban 2.5 MG Oral Tablet [ELIQUIS]
  • Aspirin 81 mg
  • Ottawa, Ontario, Canada
    The Ottawa Hospital
Apr 19, 2022

Vitiligo, Effect of Drug Trial (JAK-2 inhibitor, Topical corticosteroid)

Not yet recruiting
  • Vitiligo
  • Effect of Drug
  • JAK-2 inhibitor
  • Topical corticosteroid
  • (no location specified)
Mar 19, 2022

Metastatic Malignant Tumor in the Bone, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma Trial in

Active, not recruiting
  • Metastatic Malignant Neoplasm in the Bone
  • +2 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Scottsdale, Arizona
    Mayo Clinic in Arizona
Jan 4, 2023

Hemophagocytic Lymphohistiocytoses, Cytokine Storm Trial in Hangzhou (Dexamethasone, Etoposide, Ruxolitinib)

Not yet recruiting
  • Hemophagocytic Lymphohistiocytoses
  • Cytokine Storm
  • Hangzhou, Zhejiang, China
    The Children's Hospital of Zhejiang University School of Medicin
Aug 4, 2022

Myelofibrosis, Moderate Thrombocytopenia Trial (Selinexor)

Not yet recruiting
  • Myelofibrosis
  • Moderate Thrombocytopenia
  • (no location specified)
Jul 31, 2023

Carotid Plaque Burden in Philadelphia Negative

Recruiting
  • Myeloproliferative Neoplasm
    • Sohag, Egypt
      Faculty of Medicine
    Aug 14, 2023

    Abatacept, Treatment Compliance, Rheumatoid Arthritis Trial in Hangzhou (Janus Kinase Inhibitor, Abatacept)

    Recruiting
    • Abatacept
    • +2 more
    • Hangzhou, Zhejiang, China
      Zhejiang Provincial People's Hospital
    Jul 5, 2022

    Primary Myelofibrosis, Secondary Myelofibrosis Trial in Seattle (procedure, drug, radiation)

    Recruiting
    • Primary Myelofibrosis
    • Secondary Myelofibrosis
    • Allogeneic Hematopoietic Stem Cell Transplantation
    • +9 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Jun 21, 2022

    Vitiligo, JAK Inhibitor Trial in Canada, United States (Ruxolitinib 1.5% cream, NB-UVB phototherapy)

    Recruiting
    • Vitiligo
    • JAK Inhibitor
    • Ruxolitinib 1.5% cream
    • NB-UVB phototherapy
    • Fountain Valley, California
    • +13 more
    Jul 6, 2022

    Rheumatoid Arthritis, JAK Inhibitor, IL-6 Inhibitor Trial in Nagasaki (filgotinib 200mg/day, subcutaneous tocilizumab

    Recruiting
    • Rheumatoid Arthritis
    • +4 more
    • filgotinib 200mg/day
    • subcutaneous tocilizumab 162mg/biweekly
    • Nagasaki, Japan
      Nagasaki University Hospital
    Oct 23, 2021

    BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells, Blasts More Than 5 Percent of

    Recruiting
    • BCR-JAK2 Fusion Protein Expression
    • +11 more
    • Palo Alto, California
    • +3 more
    Oct 5, 2022

    Sarcoidosis Trial in New Haven (Abrocitinib 200 mg)

    Not yet recruiting
    • Sarcoidosis
    • Abrocitinib 200 mg
    • New Haven, Connecticut
      Yale University
    Jan 24, 2023

    Granuloma Annulare Trial in New Haven (Abrocitinib 200 mg)

    Not yet recruiting
    • Granuloma Annulare
    • Abrocitinib 200 mg
    • New Haven, Connecticut
      Yale University
    Dec 19, 2022

    Myelofibrosis Trial in Paris (Ruxolotinib)

    Completed
    • Myelofibrosis
    • Paris, France
      ROBIN
    Jul 26, 2022

    Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis Trial in Worldwide (KRT-232, TL-895)

    Recruiting
    • Myelofibrosis
    • +3 more
    • Birmingham, Alabama
    • +36 more
    May 5, 2022